港股異動丨四環醫藥漲近4% 出售若干公司股權 擬派特別息11.6港仙
格隆匯5月4日丨四環醫藥(00460.HK)漲近4%,報0.81港元,總市值76.7億港元。四環醫藥公佈,集團擬出售兩家旗下子公司重輝投資及騰為投資的全部股權,預計出售事項錄得總收益為約4600萬元。董事會建議,在出售事項完成後每股派發10.6分(相當於約11.6港仙)特別股息。重輝投資持有若干製藥公司股權,連同股東貸款轉讓,出售總代價為2.9億元;騰為投資同樣持有若干製藥公司股權,出售總代價約為1.4億元。出售事項所得款項淨額將用作集團的一般營運資金。集團解釋,出售事項能夠精簡核心業務,將資源集中核心業務的戰略發展上,更明確地確定業務定位。此外,出售的製藥公司股權多數處於早期發展階段,其中大部分公司現處於虧損狀態;集團亦未擁有這些公司的控股權益,協同效益較低。此外,出售事項可令集團重新分配管理和財務資源,以改善營運和財務狀況。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.